NeuroServo develops VEEGix, a miniaturized instant-use EEG device that provides rapid analysis of prefrontal brain waves to inform clinical decisions in suspected seizures, non-convulsive electrical storms, and anesthesia monitoring. The device was homologated by Health Canada as a Cerebral Function Monitoring (CFM) system in September 2021. VEEGix is currently deployed in about a dozen intensive care units. The company is led by CEO Nicolas Tremblay and COO Jérôme Arnaud. NeuroServo raised $2.2M in funding and intends to use the proceeds to finance commercialization of its medical innovation. The articles do not disclose other financial metrics or prior funding rounds.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2023